EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combination of 5% cysteamine and 4% nicotinamide in melasma: Efficacy, tolerability, and safety

Elisete Isabel Crocco iD, Liliana Torloni, Paula Bonilha Fernandes, Maria Elisa Barbosa Bueno de Campos, Maura Gonzaga, Fernanda Cristina Silva, João Paulo Sardin Nasario, Lucas Offenbecker Guerra, Angélica Richart Csipak, Vivienne Carduz Castilho

Journal of Cosmetic Dermatology · 2024

DOI: 10.1111/jocd.16183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, 2024. Verfasst von Elisete Isabel Crocco und 9 weiteren Autor:innen. Beteiligte Einrichtung: Rua Barata Ribeiro, São Paulo, Brazil. Hauptthemen laut MEDLINE: Cysteamine, Drug Combinations, Melanosis, Niacinamide. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Libbs Farmaceutica LTDA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Melasma is a chronic dermatosis that impacts the patient's quality of life and can present considerable challenges in terms of effective treatment.

Objective

To evaluate the effectiveness, tolerability, and safety of 5% cysteamine combined with 4% nicotinamide in female subjects with melasma.

Methods

This single‐center, single‐arm, prospective, open‐label study evaluated patients with melasma using a combination cream of 5% cysteamine and 4% nicotinamide in a progressive regimen (60 min in the first month, 120 min in the second month, and 180 min in the third month).

Results

Overall, 35 treated subjects exhibited reduced modified Melasma Area and Severity Index (mMASI) ( p < 0.001) and decreased MelasQoL scores ( p < 0.001), accompanied by improved brightness, luminosity, homogeneity, and spot intensity ( p < 0.001). Photographic and colorimetric analysis revealed smaller spots and improved homogeneity.

Limitations

Adherence to progressive daily treatment could not be evaluated long‐term.

Conclusion

A combination cream comprising 5% cysteamine and 4% nicotinamide was effective, tolerable, and safe for treating melasma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CysteamineDrug CombinationsMelanosisNiacinamideSeverity of Illness IndexAdultFemaleHumansMiddle AgedYoung AdultAdministration, CutaneousProspective StudiesQuality of LifeSkin CreamTreatment Outcome

Stichwörter der Autor:innen

cysteaminedepigmenting agentshyperpigmentationmelasmanicotinamide

Substanzen

CysteamineDrug CombinationsNiacinamide

Autor:innen und Institutionen

  • Rua Barata Ribeiro, São Paulo, Brazil.

ORCID-Profile: Elisete Isabel Crocco

Förderung

  • Libbs Farmaceutica LTDA

Zitieren

APA

Crocco, E. I., Torloni, L., Fernandes, P. B., de Campos, M. E. B. B., Gonzaga, M., Silva, F. C., Nasario, J. P. S., Guerra, L. O., Csipak, A. R., & Castilho, V. C. (2024). Combination of 5% cysteamine and 4% nicotinamide in melasma: Efficacy, tolerability, and safety. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16183

Vancouver

Crocco EI, Torloni L, Fernandes PB, de Campos MEBB, Gonzaga M, Silva FC, et al. Combination of 5% cysteamine and 4% nicotinamide in melasma: Efficacy, tolerability, and safety. Journal of Cosmetic Dermatology. 2024. doi:10.1111/jocd.16183

BibTeX
@article{Crocco2024,
  author = {Crocco, Elisete Isabel and Torloni, Liliana and Fernandes, Paula Bonilha and de Campos, Maria Elisa Barbosa Bueno and Gonzaga, Maura and Silva, Fernanda Cristina and Nasario, João Paulo Sardin and Guerra, Lucas Offenbecker and Csipak, Angélica Richart and Castilho, Vivienne Carduz},
  title = {Combination of 5% cysteamine and 4% nicotinamide in melasma: Efficacy, tolerability, and safety},
  journal = {Journal of Cosmetic Dermatology},
  year = {2024},
  doi = {10.1111/jocd.16183}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche